ACAM2000天花疫苗在美国军人中的增强安全性监测研究
该观察性队列研究通过2009至2017年每月电子病历监测,评估美军服役人员接种ACAM2000天花疫苗后30天内的心肌心包炎及心血管和神经系统不良事件发生率。共纳入897,227名ACAM2000接种者和450,000名Dryvax接种者。ACAM2000接种者经裁定心肌心包炎发生率为20.06/100,000,男性(21.8/100,000)显著高于女性(8.5/100,000),<40岁者(21.1/100,000)高于≥40岁者(6.3/100,000)。总体心血管事件率ACAM2000为113.5/100,000,Dryvax为439.3/100,000,率比0.26(95%CI 0.24-0.28);神经系统事件率分别为2.12/100,000和1.11/100,000,率比1.91(95%CI 0.71-5.10)。结论认为这些发生率与既往被动监测研究一致。
要点
- ACAM2000接种后心肌心包炎裁定发生率为20.06/100,000,男性及<40岁者更高。
- ACAM2000总体心血管事件率显著低于Dryvax,率比0.26(95%CI 0.24-0.28)。
- 神经系统事件率两组间无显著差异,率比1.91(95%CI 0.71-5.10)。
核心结论
- ACAM2000天花疫苗的心肌心包炎、特定神经系统事件及总体心血管事件发生率与既往Dryvax或ACAM2000被动监测研究一致。
研究设计与样本
- 观察性队列研究,通过2009至2017年每月监测美军服役人员电子病历,追踪接种后30天内预设的心血管和神经系统ICD代码。
- 纳入897,227名ACAM2000接种者和450,000名Dryvax接种者;Group 1代码病历逐一审查并由独立临床专家组裁定心肌心包炎,Group 2代码仅汇总报告。
主要发现
- ACAM2000接种者裁定心肌心包炎发生率为20.06/100,000,男性21.8/100,000显著高于女性8.5/100,000,<40岁者21.1/100,000高于≥40岁者6.3/100,000。
- 总体心血管事件率ACAM2000为113.5/100,000,Dryvax为439.3/100,000,率比0.26(95%CI 0.24-0.28)。
- 至少一次特定神经系统事件率ACAM2000为2.12/100,000,Dryvax为1.11/100,000,率比1.91(95%CI 0.71-5.10)。
临床怎么用
- 接种ACAM2000前应评估心血管风险,尤其关注男性及40岁以下人群的心肌心包炎风险。
- 接种后30天内监测心血管和神经系统症状,及时识别并报告不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the rates of myopericarditis (primary objective) and rates of cardiovascular and neurological adverse events (secondary objectives) in temporal association with ACAM2000® smallpox vaccine. METHODS: Observational cohort study conducted through monthly surveillance from 2009 to 2017 of electronic medical records of military service members (SM) for pre-specified cardiac and neurological International Classification of Diseases (ICD) codes reported in the 30 days following smallpox vaccination. ICD codes potentially predictive of myopericarditis and codes for encephalitis, Guillain-Barré syndrome, and sudden death were classified into Group 1. All other cardiovascular and neurological ICD codes were classified into Group 2. Medical records containing Group 1 codes were individually reviewed to confirm coding accuracy and to seek additional data in support of myopericarditis adjudication, which was performed by an independent clinical panel. Chart reviews were not performed for Group 2 codes, which were reported in aggregate only. RESULTS: 897,227 SM who received ACAM2000 smallpox vaccine and 450,000 SM who received Dryvax smallpox vaccine were included in the surveillance population. The rate of adjudicated myopericarditis among ACAM2000 smallpox vaccine recipients was 20.06/100,000 and was significantly higher for males (21.8/100,000) than females (8.5/100,000) and for those < 40 years of age (21.1/100,000) than for those 40 years or older (6.3/100,000). Overall rates for any cardiovascular event (Group 1 plus Group 2) were 113.5/100,000 for ACAM2000 vaccine and 439.3/100,000 for Dryvax vaccine; rate ratio, 0.26 (95% CI, 0.24-0.28). The rates of subjects with one or more defined neurological events were 2.12/100,000 and 1.11/100,000 for ACAM2000 and Dryvax vaccines respectively; rate ratio, 1.91 (95% CI, 0.71-5.10). CONCLUSIONS: Electronic records surveillance of the entire vaccinated SM population over a ten-year period found rates of myopericarditis, of defined neurological events, and of overall cardiac events that were consistent with those of prior passive surveillance studies involving Dryvax or ACAM2000 smallpox vaccines. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT00927719.
引用
- Decker MD, Garman PM, Hughes H, et al. Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. Vaccine. 2021. PMID: 34454787. doi:10.1016/j.vaccine.2021.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。